Immunity status against tetanus in young migrants: a seroprevalence study.


Journal

Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064

Informations de publication

Date de publication:
10 04 2020
Historique:
received: 20 03 2020
accepted: 23 03 2020
entrez: 11 4 2020
pubmed: 11 4 2020
medline: 30 3 2021
Statut: epublish

Résumé

Thanks to the highly effective vaccine, tetanus became sporadic in high-income countries with well-established primary childhood immunization programs, but it is common in low-income countries. The migrants, leaving countries with poor immunization programs or where vaccinations have been interrupted, may represent a new risk group for tetanus in host countries. A seroprevalence study was conducted to estimate the immunological status against tetanus in young migrants without vaccination documentation. After a careful assessment by vaccination services of the Local Health Authority, all migrants recently arrived in Italy were included in the serosurvey. Titers of anti-tetanus toxoid were measured using a commercial ELISA kit. Subjects were stratified by age and by WHO region. Antibody titers <0.10 IU/ml were considered to be seronegative, between 0.10 and 1.00 IU/ml as intermediate protection, and >1.00 IU/ml high protection. From January 2004 to December 2019, 2,326 blood samples were collected. Mean age was 13.9 years with no differences between WHO regions. The percentage of the subjects without protective antibodies was 22.3%, with an intermediate level was 45.2%, with high titer was 32.5%. Among migrant coming from African and Eastern Mediterranean WHO regions, the highest percentages of seronegative titers and, at the same time, the low percentages of high protective levels were found. Titers decreased with age. The significant proportion of seronegative migrants and the decrease of protective titers increasing age, confirm the importance of the evaluation of the immunological status to employ the appropriate vaccination strategy.

Sections du résumé

BACKGROUND AND AIM OF THE WORK
Thanks to the highly effective vaccine, tetanus became sporadic in high-income countries with well-established primary childhood immunization programs, but it is common in low-income countries. The migrants, leaving countries with poor immunization programs or where vaccinations have been interrupted, may represent a new risk group for tetanus in host countries. A seroprevalence study was conducted to estimate the immunological status against tetanus in young migrants without vaccination documentation.
METHODS
After a careful assessment by vaccination services of the Local Health Authority, all migrants recently arrived in Italy were included in the serosurvey. Titers of anti-tetanus toxoid were measured using a commercial ELISA kit. Subjects were stratified by age and by WHO region. Antibody titers <0.10 IU/ml were considered to be seronegative, between 0.10 and 1.00 IU/ml as intermediate protection, and >1.00 IU/ml high protection.
RESULTS
From January 2004 to December 2019, 2,326 blood samples were collected. Mean age was 13.9 years with no differences between WHO regions. The percentage of the subjects without protective antibodies was 22.3%, with an intermediate level was 45.2%, with high titer was 32.5%. Among migrant coming from African and Eastern Mediterranean WHO regions, the highest percentages of seronegative titers and, at the same time, the low percentages of high protective levels were found. Titers decreased with age.
CONCLUSIONS
The significant proportion of seronegative migrants and the decrease of protective titers increasing age, confirm the importance of the evaluation of the immunological status to employ the appropriate vaccination strategy.

Identifiants

pubmed: 32275271
doi: 10.23750/abm.v91i3-S.9438
pmc: PMC7975914
doi:

Substances chimiques

Antibodies, Bacterial 0
Tetanus Toxoid 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

77-84

Références

Ind Health. 2016 Dec 7;54(6):554-563
pubmed: 27251030
Acta Biomed. 2019 Sep 13;90(9-S):35-44
pubmed: 31517888
Occup Med (Lond). 2001 Mar;51(2):114-7
pubmed: 11307686
Occup Med (Lond). 2014 Apr;64(3):217-9
pubmed: 24706467
BMC Public Health. 2019 Nov 15;19(1):1532
pubmed: 31730455
Zoonoses Public Health. 2018 Feb;65(1):114-123
pubmed: 28791803
Vaccine. 2019 Aug 23;37(36):5439-5451
pubmed: 31296374
Euro Surveill. 2002 Jul;7(7):103-10
pubmed: 12631930
Int J Environ Res Public Health. 2018 Sep 20;15(10):
pubmed: 30241320
Public Health. 2018 May;158:110-116
pubmed: 29653865
Vaccine. 2020 Jan 29;38(5):1234-1240
pubmed: 31735506
Acta Biomed. 2020 Apr 10;91(3-S):85-91
pubmed: 32275272
Ann Ig. 2013 Sep-Oct;25(5):427-33
pubmed: 24048181
Pathog Glob Health. 2017 Mar;111(2):59-68
pubmed: 28165878
Int J Environ Res Public Health. 2016 Jun 30;13(7):
pubmed: 27376309
J Paediatr Child Health. 2011 Dec;47(12):888-92
pubmed: 22171831
Acta Biomed. 2005 Dec;76(3):157-63
pubmed: 16676565
BMC Infect Dis. 2019 Nov 21;19(1):990
pubmed: 31752738
Niger J Clin Pract. 2015 May-Jun;18(3):307-11
pubmed: 25772909
Arch Dis Child. 2005 Jan;90(1):36-40
pubmed: 15613508
Acta Biomed. 2011 Dec;82(3):208-13
pubmed: 22783717
Int J Environ Res Public Health. 2019 May 09;16(9):
pubmed: 31075829
Acta Biomed. 2019 Sep 13;90(9-S):28-34
pubmed: 31517887
Vaccine. 2014 Feb 3;32(6):639-44
pubmed: 24370712
Ann Ist Super Sanita. 2017 Jul-Sep;53(3):231-237
pubmed: 28956803
Euro Surveill. 2019 Apr;24(15):
pubmed: 30994104
Vaccine. 2016 Jun 8;34(27):3102-3108
pubmed: 27154392
Acta Biomed. 2020 Apr 10;91(3-S):63-70
pubmed: 32275269
Epidemiol Rev. 1993;15(2):265-302
pubmed: 8174658
Acta Biomed. 2019 May 23;90(2):269-278
pubmed: 31125007
Vaccine. 2018 Mar 14;36(12):1664-1672
pubmed: 29454516
Wkly Epidemiol Rec. ;92(6):53-76
pubmed: 28185446
Clin Exp Immunol. 2017 Jan;187(1):93-99
pubmed: 27279025
Infect Genet Evol. 2018 Oct;64:57-64
pubmed: 29909243
Lancet. 2019 Apr 20;393(10181):1657-1668
pubmed: 30935736
Expert Rev Vaccines. 2019 Nov;18(11):1201-1209
pubmed: 31674847
Trans R Soc Trop Med Hyg. 2000 Jul-Aug;94(4):455-9
pubmed: 11127256
Hum Vaccin. 2011 Dec;7(12):1317-25
pubmed: 22108034
Acta Biomed. 2019 Sep 13;90(9-S):21-27
pubmed: 31517886

Auteurs

Paola Affanni (P)

Array. paola.affanni@unipr.it.

Maria Eugenia Colucci (ME)

Department of Medicine and Surgery, University of Parma, Italy. mariaeugenia.colucci@unipr.it.

Emanuela Capobianco (E)

Department of Medicine and Surgery, University of Parma, Italy. emanuela.capobianco@unipr.it.

Maria Teresa Bracchi (MT)

Department of Medicine and Surgery, University of Parma, Italy. mariateresa.bracchi@unipr.it.

Roberta Zoni (R)

Department of Medicine and Surgery, University of Parma, Italy. roberta.zoni@unipr.it.

Isabella Viani (I)

Department of Medicine and Surgery, University of Parma, Italy. isabella.viani@unipr.it.

Luca Caruso (L)

Department of Medicine and Surgery, University of Parma, Italy. luca10.caruso@gmail.com.

Lucrezia Carlone (L)

Department of Medicine and Surgery, University of Parma, Italy. lucrezia.carlone@unipr.it.

Carlo Arcuri (C)

Department of Medicine and Surgery, University of Parma, Italy. carlo90030@gmail.com.

Licia Veronesi (L)

Department of Medicine and Surgery, University of Parma, Italy. licia.veronesi@unipr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH